The Prognosis and Immune Checkpoint Blockade Efficacy Prediction of Tumor-Infiltrating Immune Cells in Lung Cancer

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Aug 23

PMID 34422829

Citations 14

Authors

Xiangzheng Liu

Xueqian Shang

Jian Li

Shijie Zhang

Affiliations

Soon will be listed here.

Abstract

Backgrounds: The high morbidity and mortality of lung cancer are serious public health problems. The prognosis of lung cancer and whether to apply immune checkpoint blockade (ICB) are currently urgent problems to be solved.

Methods: Using R software, we performed Kaplan-Meier (K-M) analysis, Cox regression analysis, functional enrichment analysis, Spearman correlation analysis, and the single-sample gene set enrichment analysis.

Results: On the Tumor IMmune Estimation Resource (TIMER2.0) website, we calculated the abundance of tumor-infiltrating immune cells (TIICs) of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. B cell and myeloid dendritic cell (DC1) were independent prognostic factors for LUAD and LUSC patients, respectively. Enrichment analysis confirmed that genes highly related to B cell or DC1 were closely related to the immune activation of lung cancer patients. In terms of adaptive immune resistance markers, CD8A, CD8B, immunomodulators (immunostimulants, major histocompatibility complex, receptors, and chemokines), immune-related pathways, tumor microenvironment score, and TIICs, high B cell/DC1 infiltration tissue was inflamed and immune-activated and might benefit more from the ICB. Genes most related to B cell [CD19, toll-like receptor 10 (TLR10), and Fc receptor-like A (FCRLA)] and DC1 (ITGB2, LAPTM5, and SLC7A7) partially clarified the roles of B cell/DC1 in predicting ICB efficacy. Among the 186 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, there were three and four KEGG pathways, which partially explained the molecular mechanisms by which B cell and DC1 simultaneously predicted the prognosis and efficacy of immunotherapy, respectively. Among five immune subtypes, the abundance of B cell/DC1 and expression of six hub genes were higher in immune C2, C3, and C6.

Conclusion: B cell and DC1 could predict the prognosis and ICB efficacy of LUAD and LUSC patients, respectively. The six hub genes and seven KEGG pathways might be novel immunotherapy targets. Immune C2, C3, and C6 subtypes of lung cancer patients might benefit more from ICB therapy.

Citing Articles

Novel Assignment of Gene Markers to Hematological and Immune Cells Based on Single-Cell Transcriptomics.

Rosa E, Alonso-Moreda N, Berral-Gonzalez A, Sanchez-Luis E, Gonzalez-Velasco O, Sanchez-Santos J Int J Mol Sci. 2025; 26(2).

PMID: 39859519 PMC: 11765818. DOI: 10.3390/ijms26020805.

Lysosomal transmembrane protein 5: Impact on immune cell function and implications for immune-related deficiencies.

Sun P, Liao S, Sang P, Liu M, Yang J Heliyon. 2024; 10(17):e36705.

PMID: 39281638 PMC: 11401081. DOI: 10.1016/j.heliyon.2024.e36705.

Functional exploration and drug prediction on programmed cell death-related biomarkers in lung adenocarcinoma.

Zhang X, Liu T, Hao Y, Guo H, Li B Heliyon. 2024; 10(17):e36616.

PMID: 39281570 PMC: 11401088. DOI: 10.1016/j.heliyon.2024.e36616.

Multiplex plasma protein assays as a diagnostic tool for lung cancer.

Ahamed M, Forshed J, Levitsky A, Lehtio J, Bajalan A, Pernemalm M Cancer Sci. 2024; 115(10):3439-3454.

PMID: 39080998 PMC: 11447887. DOI: 10.1111/cas.16300.

Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes.

Karapetyan L, Abushukair H, Li A, Knight A, Nedal Al Bzour A, MacFawn I Front Immunol. 2023; 14:1171978.

PMID: 37435077 PMC: 10332263. DOI: 10.3389/fimmu.2023.1171978.

References

Lin H, Cheng C, Chen D, Chen Y, Park J . Coexpression and expression quantitative trait loci analyses of the angiogenesis gene-gene interaction network in prostate cancer. Transl Cancer Res. 2017; 5(Suppl 5):S951-S963. PMC: 5485921. DOI: 10.21037/tcr.2016.10.55. View

Bai M, Grieshaber-Bouyer R, Wang J, Schmider A, Wilson Z, Zeng L . CD177 modulates human neutrophil migration through activation-mediated integrin and chemoreceptor regulation. Blood. 2017; 130(19):2092-2100. PMC: 5680608. DOI: 10.1182/blood-2017-03-768507. View

Ostermann G, Weber K, Zernecke A, Schroder A, Weber C . JAM-1 is a ligand of the beta(2) integrin LFA-1 involved in transendothelial migration of leukocytes. Nat Immunol. 2002; 3(2):151-8. DOI: 10.1038/ni755. View

Glowacka W, Alberts P, Ouchida R, Wang J, Rotin D . LAPTM5 protein is a positive regulator of proinflammatory signaling pathways in macrophages. J Biol Chem. 2012; 287(33):27691-702. PMC: 3431655. DOI: 10.1074/jbc.M112.355917. View

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

Liu Y, Wu L, Ao H, Zhao M, Leng X, Liu M . Prognostic implications of autophagy-associated gene signatures in non-small cell lung cancer. Aging (Albany NY). 2019; 11(23):11440-11462. PMC: 6932887. DOI: 10.18632/aging.102544. View

Warde-Farley D, Donaldson S, Comes O, Zuberi K, Badrawi R, Chao P . The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010; 38(Web Server issue):W214-20. PMC: 2896186. DOI: 10.1093/nar/gkq537. View

Carter R, Fearon D . CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992; 256(5053):105-7. DOI: 10.1126/science.1373518. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

10.

Reshetnikova E, Mechetina L, Volkova O, Guselnikov S, Chikaev N, Kovesdi D . Differential expression of FCRLA in naïve and activated mouse B cells. Cell Immunol. 2011; 272(2):182-92. PMC: 3250215. DOI: 10.1016/j.cellimm.2011.10.013. View

11.

Dai W, Feng J, Hu X, Chen Y, Gu Q, Gong W . SLC7A7 is a prognostic biomarker correlated with immune infiltrates in non-small cell lung cancer. Cancer Cell Int. 2021; 21(1):106. PMC: 7905560. DOI: 10.1186/s12935-021-01781-7. View

12.

Zhang Z, Parker M, Graw S, Novikova L, Fedosyuk H, Fontes J . -GlcNAc homeostasis contributes to cell fate decisions during hematopoiesis. J Biol Chem. 2018; 294(4):1363-1379. PMC: 6349094. DOI: 10.1074/jbc.RA118.005993. View

13.

Remon J, Besse B . Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. Curr Opin Oncol. 2017; 29(2):97-104. DOI: 10.1097/CCO.0000000000000351. View

14.

Waniczek D, Lorenc Z, Snietura M, Wesecki M, Kopec A, Muc-Wierzgon M . Tumor-Associated Macrophages and Regulatory T Cells Infiltration and the Clinical Outcome in Colorectal Cancer. Arch Immunol Ther Exp (Warsz). 2017; 65(5):445-454. PMC: 5602054. DOI: 10.1007/s00005-017-0463-9. View

15.

He R, Zuo S . A Robust 8-Gene Prognostic Signature for Early-Stage Non-small Cell Lung Cancer. Front Oncol. 2019; 9:693. PMC: 6684755. DOI: 10.3389/fonc.2019.00693. View

16.

Ren Q, Zhu P, Zhang H, Ye T, Liu D, Gong Z . Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer. Cancer Cell Int. 2020; 20:92. PMC: 7092673. DOI: 10.1186/s12935-020-01173-3. View

17.

Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov J . Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27(12):1739-40. PMC: 3106198. DOI: 10.1093/bioinformatics/btr260. View

18.

Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

19.

He L, Chen J, Xu F, Li J . Prognostic Implication of a Metabolism-Associated Gene Signature in Lung Adenocarcinoma. Mol Ther Oncolytics. 2020; 19:265-277. PMC: 7658576. DOI: 10.1016/j.omto.2020.09.011. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View